Prof. Dr. Halil KÖMEK

1. The Eye-Black Sign on 18F-FDG PET/CT in Endometrial Adenocarcinoma Without Prior Systemic Therapy: A Rare Imaging Pitfall

Güzel F., Nacir M., Çetin A., Alakuş M. F., KÖMEK H.

Clinical Nuclear Medicine , cilt.51, sa.10, ss.939-940, 2026 (SCI-Expanded, Scopus)

2. 68Ga-CXCR4-targeted PET/CT Outperforms 18F-FDG PET/CT in FLT3-mutated AML M1 With Granulocytic Sarcoma: Theranostic Insights

Beyler Ö., KÖMEK H., Güzel Y., DEMİR C., Can C.

Clinical Nuclear Medicine , cilt.51, sa.6, 2026 (SCI-Expanded, Scopus)

3. Comparison of the diagnostic accuracy of [68Ga]Ga-Trivehexin PET/computed tomography and [18F]FDG PET/computed tomography in nodal staging of various solid tumors

Karaoğlan H., Can C., Akdeniz N., Şimşek D. H., Güzel Y., Soylu B., et al.

Nuclear Medicine Communications , cilt.47, sa.4, ss.470-478, 2026 (SCI-Expanded, Scopus)

4. New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study

Karpinski M. J., Civan C., Rauscher I., Güven O., Eiber M., Hoberück S., et al.

The Lancet Oncology , cilt.27, sa.4, ss.480-490, 2026 (SCI-Expanded, Scopus)

5. Istanbul PSMA PET/CT criteria (IPPC): an imaging-based approach to patient selection for active surveillance

KABASAKAL L., Akçay K., Selçuk A. N., Beydağı G., AKGÜN E., Akyel R., et al.

European Journal of Nuclear Medicine and Molecular Imaging , cilt.53, sa.5, ss.3042-3055, 2026 (SCI-Expanded, Scopus)

6. Role of Volumetric Parameters Derived From Ga-68 PSMA PET-CT in Predicting Treatment Response

Uyar A., Taşdemir B., Tuzcu Ş. A., Oruç Z., KÖMEK H.

Prostate , cilt.86, sa.3, ss.372-376, 2026 (SCI-Expanded, Scopus)

7. Association of Fat and Muscle Mass With Overall Survival in Patients With Metastatic Prostate Cancer Treated With Enzalutamide, Abiraterone, and Docetaxel

SOLMAZ İ., KÖMEK H., Kayan F., Can C., Kaplan İ., Kiliç R., et al.

Clinical Genitourinary Cancer , cilt.24, sa.1, 2026 (SCI-Expanded, Scopus)

8. Predictive value of the FIB-4 index, APRI, ALBI score, and GPR for overall survival in treatment-naïve metastatic colorectal cancer patients

Yıldırım M. S., Güzel Y., Can C., Kaplan İ., Şenses V., SOLMAZ İ., et al.

BMC Gastroenterology , cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)

9. Prognostic Role of Sarcopenia in High-grade Lymphoma: A Retrospective PET/CT-Based Study

Beyler Ö., Güzel Y., DEMİR C., Yıldırım S., Can C., KÖMEK H.

Acta Haematologica Oncologica Turcica , cilt.58, sa.2, ss.110-114, 2025 (Scopus, TRDizin)

10. Contribution of tubarial salivary gland function detected through 68Ga-prostate-specific membrane antigen PET/computed tomography to total salivary gland function

Kaplan İ., Yeprem Ö., KÖMEK H., Kepenek F., Güzel Y., Karaoǧlan H., et al.

Nuclear Medicine Communications , cilt.46, sa.6, ss.553-557, 2025 (SCI-Expanded, Scopus)

11. Superiority of 68Ga-Trivehexin PET/CT Over 18F-FDG PET/CT in the Evaluation of Lymph Nodes in Patients With Breast Cancer

KÖMEK H., Güzel Y., Kaplan İ., Yilmaz E. E., Can C.

Clinical Nuclear Medicine , cilt.50, sa.3, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Pseudoprogression Shown on 18F-FDG PET/CT After Pembrolizumab Treatment in a Case of Metastatic Bladder Cancer Metastatik Mesane Kanserli Bir Olguda Pembrolizumab Tedavisi Sonrası 18F-FDG PET/BT’de Gösterilen Psödoprogresyon

Kaya F., KÖMEK H., Dursun İ. H., Şenses V., Gündoğan C.

Molecular Imaging and Radionuclide Therapy , cilt.34, sa.1, ss.70-72, 2025 (ESCI, Scopus, TRDizin)

13. The inferior performance of [68Ga]Ga-FAPI-04 PET/CT as a diagnostic and theranostic biomarker in [177Lu]Lu-DOTATATE refractory well-differentiated neuroendocrine tumors

Has Simsek D., Guzel Y., Denizmen D., Sanli Y., Buyukkaya F., KOVAN B., et al.

European Journal of Nuclear Medicine and Molecular Imaging , cilt.51, sa.3, ss.828-840, 2024 (SCI-Expanded, Scopus)

14. Comparison of 68GA-FAPI-04 PET/CT and 18F-FDG PET/CT in detection of metastatic bone disease in various cancers Comparaison de la TEP/TDM 68GA-FAPI-04 et de la TEP/TDM 18F-FDG dans la détection de la maladie osseuse métastatique dans divers cancers

Kepenek F., Kaplan İ., CAN C., Karaoğlan H., Güzel Y., KÖMEK H.

Medecine Nucleaire , cilt.47, sa.4, ss.200-207, 2023 (SCI-Expanded, Scopus)

15. Comparison of the role of 18F-fluorodeoxyglucose PET/computed tomography and 68Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma

Güzel Y., KÖMEK H., Can C., Kaplan İ., Kepenek F., Ebinç S., et al.

Nuclear Medicine Communications , cilt.44, sa.7, ss.631-639, 2023 (SCI-Expanded, Scopus)

16. The prognostic role of whole-body volumetric 68GA-DOTATATE PET/computed tomography parameters in patients with gastroenteropancreatic neuroendocrine tumor treated with 177LU-DOTATATE

Kepenek F., KÖMEK H., Can C., Kaplan İ., Altindaǧ S., Gündoǧan C.

Nuclear Medicine Communications , cilt.44, sa.6, ss.509-517, 2023 (SCI-Expanded, Scopus)

17. 68GA-FAPI-04 PET/CT Versus 18F-FDG PET/CT in Imaging of Malignant Mixed Germ Cell Testicular Tumor

Kaplan I., Can C., Güzel Y., Alabalik U., KÖMEK H.

Clinical Nuclear Medicine , cilt.48, sa.4, 2023 (SCI-Expanded, Scopus)

18. Comparison of 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT in patients with non-small cell lung cancer

Can C., Kepenek F., KÖMEK H., Gündoǧan C., Kaplan İ., Taşdemir B., et al.

Nuclear Medicine Communications , cilt.43, sa.10, ss.1084-1091, 2022 (SCI-Expanded, Scopus)

19. The role of basal metabolic and volumetric 18F-FDG PET/CT parameters and their changes in predicting pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy

Kepenek F., Karaoğlan H., Can C., KÖMEK H., Kaplan İ., Etem H., et al.

Hellenic Journal of Nuclear Medicine , cilt.25, sa.3, ss.235-246, 2022 (SCI-Expanded, Scopus)

20. The effect of coronavirus disease 2019 pneumonia on myocardial ischemia detected by single-photon emission computed tomography myocardial perfusion imaging

Bilge Ö., KÖMEK H., Kepenek F., Taştan E., Gündoǧan C., Tatli İ., et al.

Nuclear Medicine Communications , cilt.43, sa.7, ss.756-762, 2022 (SCI-Expanded, Scopus)

21. The Prognostic Value of18F-FDG PET/CT Metabolic Parameters in Predicting Treatment Response Before EGFR TKI Treatment in Patients with Advanced Lung Adenocarcinoma İlerlemiş Akciğer Adenokarsinomu Olan Hastalarda EGFR TKI Tedavisi Öncesi Tedavi Yanıtını Öngörmede18F-FDG PET/BT Metabolik Parametrelerinin Prognostik Değeri

AGÜLOĞLU N., Akyol M., KÖMEK H., Katgı N.

Molecular Imaging and Radionuclide Therapy , cilt.31, sa.2, ss.104-113, 2022 (Scopus, TRDizin)

22. 68Ga-FAPI-04 PET/CT Versus 18F-FDG PET/CT in Malignant Peritoneal Mesothelioma

Gündoǧan C., Güzel Y., KÖMEK H., Etem H., Kaplan İ.

Clinical Nuclear Medicine , cilt.47, sa.2, 2022 (SCI-Expanded, Scopus)

23. Comparison of 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT in the staging and restaging of gastric adenocarcinoma

Gündoǧan C., KÖMEK H., Can C., Yildirim Ö. A., Kaplan İ., Erdur E., et al.

Nuclear Medicine Communications , cilt.43, sa.1, ss.64-72, 2022 (SCI-Expanded, Scopus)

24. The prognostic role of baseline 18F-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy El papel pronóstico del SUVmáx basal y cambio del SUVmáx en la PET/TC con18F-FDG en pacientes con cáncer de mama con ganglios positivos que reciben quimioterapia neoadyuvante

CAN C., Akdeniz N., KÖMEK H., Gündoğan C., Urakçı Z., Işıkdoğan A.

Revista Espanola de Medicina Nuclear e Imagen Molecular , cilt.41, sa.1, ss.3-10, 2022 (SCI-Expanded, Scopus)

25. The effect of prior COVID-19 infection on coronary microvascular dysfunction

Bilge Ö., ÇAP M., Kepenek F., Erdogan E., Tatlı İ., Öztürk C., et al.

Acta Cardiologica , cilt.77, sa.8, ss.693-698, 2022 (SCI-Expanded, Scopus)

26. A case with68ga-fapi positive and18f-fdg negative breast cancer 68 ga-fapi pozitif,18f-fdg negatif meme kanseri olgusu

KÖMEK H., Gündoğan C., ETEM H., Can C.

Molecular Imaging and Radionuclide Therapy , cilt.30, sa.3, ss.201-204, 2021 (ESCI, Scopus, TRDizin)

27. False-Positive 68Ga-Fibroblast Activation Protein-Specific Inhibitor Uptake of Benign Lymphoid Tissue in a Patient with Breast Cancer

Gundogan C., Guzel Y., Can C., Alabalik U., KÖMEK H.

Clinical Nuclear Medicine , cilt.46, sa.8, 2021 (SCI-Expanded, Scopus)

28. 68Ga-FAPI Uptake of Thyroiditis in a Patient with Breast Cancer

Can C., Gundogan C., Guzel Y., Kaplan İ., KÖMEK H.

Clinical Nuclear Medicine , cilt.46, sa.8, ss.683-685, 2021 (SCI-Expanded, Scopus)

29. 68Ga-FAPI PET/CT Versus 68Ga-DOTATATE PET/CT in the Evaluation of a Patient with Neuroendocrine Tumor

KÖMEK H., Gündoǧan C., Can C.

Clinical Nuclear Medicine , cilt.46, sa.5, 2021 (SCI-Expanded, Scopus)

30. Is68Ga-Prostate-Specific Membrane Antigen PET/CT Superior than18F-FDG PET/CT for Evaluation of Metastatic Osteosarcoma?

Can C., Gündoǧan C., KÖMEK H.

Clinical Nuclear Medicine , cilt.46, sa.4, 2021 (SCI-Expanded, Scopus)

31. Role of 68Ga-PSMA PET/CT parameters in treatment evaluation and survival prediction in prostate cancer patients compared with biochemical response assessment

Can C., Gündoǧan C., YILDIRIM Ö. A., Poyraz K., Güzel Y., KÖMEK H.

Hellenic Journal of Nuclear Medicine , cilt.24, sa.1, ss.25-35, 2021 (SCI-Expanded, Scopus)

32. Evaluation of dual time-point fluorodeoxyglucose PET/computed tomography imaging in gastric cancer

Tasdemir B., Güzel Y., KÖMEK H., Can C.

Nuclear Medicine Communications , cilt.41, sa.12, ss.1322-1327, 2020 (SCI-Expanded, Scopus)

33. Associations of volumetric whole-body 18F-FDG PET/CT parameters with the CA 19-9 level and haemogram parameters in pancreatic adenocarcinoma

Araç E., Can C., KÖMEK H.

Hellenic Journal of Nuclear Medicine , cilt.23, sa.1, ss.40-47, 2020 (SCI-Expanded, Scopus)

34. Contribution of 5th minute and 2nd hour images to standard imaging in (68Ga)PSMA 11 PET/CT

Can C., KÖMEK H.

Annals of Nuclear Medicine , cilt.34, sa.3, ss.163-173, 2020 (SCI-Expanded, Scopus)

35. The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax

Yilmaz U., KÖMEK H., Can C., Altindag S.

Annals of Nuclear Medicine , cilt.33, sa.8, ss.545-553, 2019 (SCI-Expanded, Scopus)

36. Prognostic value of 68 Ga PSMA I&T PET/CT SUV parameters on survival outcome in advanced prostat cancer

KÖMEK H., Can C., Yilmaz U., Altindag S.

Annals of Nuclear Medicine , cilt.32, sa.8, ss.542-552, 2018 (SCI-Expanded, Scopus)

37. The effect on survival and mortality of the highest suvmax value on metastatic foci in postoperative kidney tumors

KÖMEK H., Altindag S., CAN C., AGÜLOĞLU N., Morcali H., Kepenek F., et al.

Nigerian Journal of Clinical Practice , cilt.21, sa.2, ss.163-169, 2018 (SCI-Expanded, Scopus)

38. The prognostic value of preoperative PET/CT evaluation of maximum standardized uptake value in renal cell carcinomas

KÖMEK H., Altindag S., Can C., AGÜLOĞLU N., Morcali H., TÜZÜN A., et al.

Annali Italiani di Chirurgia , cilt.88, sa.1, ss.48-54, 2017 (SCI-Expanded, Scopus)

39. Is there any significance of lung cancer histology to compare the diagnostic accuracies of 18F-FDG-PET/CT and 99mTc-MDP BS for the detection of bone metastases in advanced NSCLC?

Inal A., Kaplan M. A., Kucukoner M., Urakci Z., Dostbil Z., KÖMEK H., et al.

Wspolczesna Onkologia , cilt.18, sa.2, ss.106-110, 2014 (Scopus)

Yayınlar & Eserler

Yayın

Yayın (WoS)

Yayın (Scopus)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Açık Erişim